GLOBEALERT
Health● Low33m ago · Nov 19, 2026, 4:30 AM

A new drug that doubles pancreatic cancer survival arrives in Europe: patients ask Spain to accelerate its funding

GlobeAlert Desk · curated from Infobae · Argentina · Western Europe

Daraxonrasib has managed to increase median overall survival from 6.7 months to 12.4 months.

GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text. How we score stories.

GlobeAlert context

What the desk knows about this story

Threat level
1 Low

Scored from severity, scale, escalation potential and source agreement. Below the alert threshold.

Sources
1 publisher

Single-source so far. Treat details as unconfirmed until more publishers report.

Category
Health

Not flagged as developing.

More from Argentina

More in Health